TY - JOUR
T1 - Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus
T2 - An international multicentre PRINTO study
AU - Miettunen, Paivi M.
AU - Pistorio, Angela
AU - Palmisani, Elena
AU - Ravelli, Angelo
AU - Silverman, Earl
AU - Oliveira, Sheila
AU - Alessio, Maria
AU - Cuttica, Ruben
AU - Mihaylova, Dimitrina
AU - Espada, Graciela
AU - Pasic, Srdjan
AU - Insalaco, Antonella
AU - Ozen, Seza
AU - Porras, Oscar
AU - Sztajnbok, Flavio
AU - Lazarevic, Dragana
AU - Martini, Alberto
AU - Ruperto, Nicolino
PY - 2013/9
Y1 - 2013/9
N2 - Objectives: To evaluate therapeutic approaches and response to therapy in juvenile systemic lupus erythematosus (SLE) with renal involvement in a large prospective international cohort from four geographic areas. Methods New onset and flared patients with active renal disease (proteinuria ≥0.5 g/24 h) were enrolled in 2001.2004. Therapeutic approaches and disease activity parameters were analysed at baseline, 6, 12 and 24 months. Response was assessed by the PRINTO/ACR criteria. Results: 218/557 (79.8% female subjects, 117 new onset and 101 flared) patients with active renal disease were identified; 66 patients were lost to follow-up and 11 died. Mean age at disease onset for new onset group was higher than for flared group (13.1 vs 10.2 years, p
AB - Objectives: To evaluate therapeutic approaches and response to therapy in juvenile systemic lupus erythematosus (SLE) with renal involvement in a large prospective international cohort from four geographic areas. Methods New onset and flared patients with active renal disease (proteinuria ≥0.5 g/24 h) were enrolled in 2001.2004. Therapeutic approaches and disease activity parameters were analysed at baseline, 6, 12 and 24 months. Response was assessed by the PRINTO/ACR criteria. Results: 218/557 (79.8% female subjects, 117 new onset and 101 flared) patients with active renal disease were identified; 66 patients were lost to follow-up and 11 died. Mean age at disease onset for new onset group was higher than for flared group (13.1 vs 10.2 years, p
UR - http://www.scopus.com/inward/record.url?scp=84881479557&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881479557&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2012-201937
DO - 10.1136/annrheumdis-2012-201937
M3 - Article
C2 - 23100607
AN - SCOPUS:84881479557
SN - 0003-4967
VL - 72
SP - 1503
EP - 1509
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 9
ER -